



Press release

Stockholm, March 3, 2011

Year-End Report 2010

Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation products for therapy, diagnostic imaging, and other applications based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Year-End Report for 2010.

Financial Highlights

- Revenue for the year was SEK 27.5 (23.8) million
- Net loss for the year amounted to SEK -21.9 (-37.4) million
- Earnings per share was SEK -0.25 (-0.66)
- Cash flow from current operations was SEK -15.7 (-39.3) million
- SEK 27.6 million raised in additional financing of which 23.8 in cash

Key Corporate Highlights

- During the year Affibody and Amylin entered into a license agreement regarding the Albumod™ platform.
- Affibody has also signed an agreement with an undisclosed company regarding its HER2 molecular imaging program, which includes ABY-025.
- The Swedish Governmental Agency for Innovation Systems (VINNOVA) awarded Affibody a grant from their Innovations for Future Health program. The grant will enable Affibody to take the Albumod™ technology to human clinical testing.
- The Swedish MPA (Läkemedelsverket) has approved an exploratory clinical study in breast cancer patients at Uppsala University Hospital, Uppsala, Sweden with Affibody’s lead molecular imaging agent, ABY-025.
- A share issue directed to existing shareholders raised SEK 27.6 million gross to the company after which the total number of shares increased to 102 858 403.

David Bejker CEO, said: “*Affibody is now firmly moving towards a new phase in its development. The Uppsala imaging study continues to recruit patients and the Albumod™ platform is progressing well towards the clinic. We have had the pleasure to announce two important collaborations during the year. The top line growth has been solid despite negative currency fluctuations. It is with great expectations we look forward to 2011.*”

Enquiries

David Bejker, CEO
Johan Stuart CFO

+46 706 454 948
+46 706 644 096

About Affibody

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.

Affibody has ongoing commercial relationships with several companies including Amylin, Swedish Orphan Biovitrum, GE, and Thermo Fisher.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include HealthCap and Investor Growth Capital.

Further information can be found at: www.affibody.com



Lindhagensgatan 133, SE-112 51 Stockholm, Sweden.
Tel +46 8 59 88 38 00, Fax +46 8 59 88 38 01, www.affibody.com